Literature DB >> 33471027

Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women.

Sagar B Dugani1,2, M Vinayaga Moorthy1,3, Chunying Li1,3, Olga V Demler1,3, Alawi A Alsheikh-Ali4, Paul M Ridker3,5, Robert J Glynn1,3, Samia Mora1,3,5.   

Abstract

Importance: Risk profiles for premature coronary heart disease (CHD) are unclear. Objective: To examine baseline risk profiles for incident CHD in women by age at onset. Design, Setting, and Participants: A prospective cohort of US female health professionals participating in the Women's Health Study was conducted; median follow-up was 21.4 years. Participants included 28 024 women aged 45 years or older without known cardiovascular disease. Baseline profiles were obtained from April 30, 1993, to January 24, 1996, and analyses were conducted from October 1, 2017, to October 1, 2020. Exposures: More than 50 clinical, lipid, inflammatory, and metabolic risk factors and biomarkers. Main Outcomes and Measures: Four age groups were examined (<55, 55 to <65, 65 to <75, and ≥75 years) for CHD onset, and adjusted hazard ratios (aHRs) were calculated using stratified Cox proportional hazard regression models with age as the time scale and adjusting for clinical factors. Women contributed to different age groups over time.
Results: Of the clinical factors in the women, diabetes had the highest aHR for CHD onset at any age, ranging from 10.71 (95% CI, 5.57-20.60) at CHD onset in those younger than 55 years to 3.47 (95% CI, 2.47-4.87) at CHD onset in those 75 years or older. Risks that were also noted for CHD onset in participants younger than 55 years included metabolic syndrome (aHR, 6.09; 95% CI, 3.60-10.29), hypertension (aHR, 4.58; 95% CI, 2.76-7.60), obesity (aHR, 4.33; 95% CI, 2.31-8.11), and smoking (aHR, 3.92; 95% CI, 2.32-6.63). Myocardial infarction in a parent before age 60 years was associated with 1.5- to 2-fold risk of CHD in participants up to age 75 years. From approximately 50 biomarkers, lipoprotein insulin resistance had the highest standardized aHR: 6.40 (95% CI, 3.14-13.06) for CHD onset in women younger than 55 years, attenuating with age. In comparison, weaker but significant associations with CHD in women younger than 55 years were noted (per SD increment) for low-density lipoprotein cholesterol (aHR, 1.38; 95% CI, 1.10-1.74), non-high-density lipoprotein cholesterol (aHR, 1.67; 95% CI, 1.36-2.04), apolipoprotein B (aHR, 1.89; 95% CI, 1.52-2.35), triglycerides (aHR, 2.14; 95% CI, 1.72-2.67), and inflammatory biomarkers (1.2- to 1.8-fold)-all attenuating with age. Some biomarkers had similar CHD age associations (eg, physical inactivity, lipoprotein[a], total high-density lipoprotein particles), while a few had no association with CHD onset at any age. Most risk factors and biomarkers had associations that attenuated with increasing age at onset. Conclusions and Relevance: In this cohort study, diabetes and insulin resistance, in addition to hypertension, obesity, and smoking, appeared to be the strongest risk factors for premature onset of CHD. Most risk factors had attenuated relative rates at older ages.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33471027      PMCID: PMC7818181          DOI: 10.1001/jamacardio.2020.7073

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   30.154


  21 in total

1.  Lipoprotein subtypes after testosterone therapy in transmasculine adolescents.

Authors:  Kate Millington; Yee-Ming Chan
Journal:  J Clin Lipidol       Date:  2021-10-02       Impact factor: 4.766

2.  Jujuboside A Ameliorates Myocardial Apoptosis and Inflammation in Rats with Coronary Heart Disease by Inhibiting PPAR-α Signaling Pathway.

Authors:  Chunfang Hu; Zhiyuan Zhang; Guixian Song; Li Zhu; Ruzhu Wang; Zhongbao Ruan
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-24       Impact factor: 2.650

3.  Modeling the Recommended Age for Initiating Coronary Artery Calcium Testing Among At-Risk Young Adults.

Authors:  Omar Dzaye; Alexander C Razavi; Zeina A Dardari; Leslee J Shaw; Daniel S Berman; Matthew J Budoff; Michael D Miedema; Khurram Nasir; Alan Rozanski; John A Rumberger; Carl E Orringer; Sidney C Smith; Ron Blankstein; Seamus P Whelton; Martin Bødtker Mortensen; Michael J Blaha
Journal:  J Am Coll Cardiol       Date:  2021-10-19       Impact factor: 27.203

4.  Importance of Sex Differences in Research on Cardiovascular Disease Prevention.

Authors:  Miho Iida
Journal:  J Atheroscler Thromb       Date:  2022-04-16       Impact factor: 4.394

Review 5.  Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials.

Authors:  John R Ussher; Amanda A Greenwell; My-Anh Nguyen; Erin E Mulvihill
Journal:  Diabetes       Date:  2022-02-01       Impact factor: 9.461

6.  Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia-a randomized controlled feeding trial.

Authors:  Cara B Ebbeling; Amy Knapp; Ann Johnson; Julia M W Wong; Kimberly F Greco; Clement Ma; Samia Mora; David S Ludwig
Journal:  Am J Clin Nutr       Date:  2022-01-11       Impact factor: 7.045

7.  Secular incidence trends and effect of population aging on mortality due to type 1 and type 2 diabetes mellitus in China from 1990 to 2019: findings from the Global Burden of Disease Study 2019.

Authors:  Yongze Li; Chenxi Guo; Yanli Cao
Journal:  BMJ Open Diabetes Res Care       Date:  2021-11

8.  Association of Plasma Branched-Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women.

Authors:  Rikuta Hamaya; Samia Mora; Patrick R Lawler; Nancy R Cook; Paul M Ridker; Julie E Buring; I-Min Lee; JoAnn E Manson; Deirdre K Tobias
Journal:  Circ Genom Precis Med       Date:  2021-07-15

Review 9.  Low Carbohydrate Dietary Approaches for People With Type 2 Diabetes-A Narrative Review.

Authors:  Sean D Wheatley; Trudi A Deakin; Nicola C Arjomandkhah; Paul B Hollinrake; Trudi E Reeves
Journal:  Front Nutr       Date:  2021-07-15

10.  Elevated LDL Cholesterol with a Carbohydrate-Restricted Diet: Evidence for a "Lean Mass Hyper-Responder" Phenotype.

Authors:  Nicholas G Norwitz; David Feldman; Adrian Soto-Mota; Tro Kalayjian; David S Ludwig
Journal:  Curr Dev Nutr       Date:  2021-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.